{"pmid":32388452,"title":"Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients.","text":["Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients.","Mult Scler Relat Disord","Haji Akhoundi, Fahimeh","Sahraian, Mohammad Ali","Naser Moghadasi, Abdorreza","32388452"],"journal":"Mult Scler Relat Disord","authors":["Haji Akhoundi, Fahimeh","Sahraian, Mohammad Ali","Naser Moghadasi, Abdorreza"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388452","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.msard.2020.102164","topics":["Prevention"],"weight":1,"_version_":1666428892596928512,"score":9.490897,"similar":[{"pmid":32388458,"title":"Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.","text":["Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.","Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection. Recent evidence accumulates that adamantanes, widely used in different neurological diseases, could be repurposed for COVID-19. We hereby report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis (n=10), Parkinson's disease (n=5) or cognitive impairment (n=7). In all patients infection with SARS-CoV-2 was confirmed by rtPCR of nasopharyngeal swabs. They were receiving treatment with either amantadine (n=15) or memantine (n=7) in stable registered doses. All of them had two-week quarantine since documented exposure and none of them developed clinical manifestations of infectious disease. They also did not report any significant changes in neurological status in the course of primary nervous system disease. Above results warrant further studies on protective effects of adamantanes against COVID-19 manifestation, especially in subjects suffering from neurological disease.","Mult Scler Relat Disord","Rejdak, Konrad","Grieb, Pawel","32388458"],"abstract":["Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection. Recent evidence accumulates that adamantanes, widely used in different neurological diseases, could be repurposed for COVID-19. We hereby report on a questionnaire-based study performed to assess severity of COVID-19 in patients suffering from multiple sclerosis (n=10), Parkinson's disease (n=5) or cognitive impairment (n=7). In all patients infection with SARS-CoV-2 was confirmed by rtPCR of nasopharyngeal swabs. They were receiving treatment with either amantadine (n=15) or memantine (n=7) in stable registered doses. All of them had two-week quarantine since documented exposure and none of them developed clinical manifestations of infectious disease. They also did not report any significant changes in neurological status in the course of primary nervous system disease. Above results warrant further studies on protective effects of adamantanes against COVID-19 manifestation, especially in subjects suffering from neurological disease."],"journal":"Mult Scler Relat Disord","authors":["Rejdak, Konrad","Grieb, Pawel"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388458","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.msard.2020.102163","keywords":["adamantanes","amantadine","covid-19","cognitive impairment","memantine","multiple sclerosis","pd","protection","sars-cov-2"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666428892563374081,"score":66.81005},{"pmid":32329046,"title":"[EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic].","text":["[EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic].","INTRODUCTION: The current SARS-CoV-2 pandemic is forcing neurologists to carry out a series of adaptations in the management of multiple sclerosis. Neurologists must weigh up the need to start or continue disease-modifying treatments against the risk of infection, the risk of complications from the infection, and the risk of multiple sclerosis activity. Since this is an unprecedented situation, most decisions are being made on the basis of a theoretical approach and the criteria of each neurologist. AIMS: The aim of this study is conduct a literature search to collect available evidence on the relationship between disease-modifying therapies in multiple sclerosis and SARS-CoV-2 infection. This evidence, together with the experience of the authors in the management of patients with multiple sclerosis during the pandemic, will make it possible to offer some proposals for the treatment and follow-up of patients in this epidemiological context. DEVELOPMENT: After the literature search and our experience in the management of patients, a number of proposals for treatment are established for each drug, which must necessarily be individualised for each patient, since, in these exceptional circumstances, their peculiarities can affect the prognosis. CONCLUSIONS: The neurologist should be aware of current evidence to assess the risk-benefit of starting, maintaining and stopping disease-modifying therapies in multiple sclerosis during the pandemic.","Rev Neurol","Costa-Frossard, L","Moreno-Torres, I","Meca-Lallana, V","Garcia-Dominguez, J M","En Representacion Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autonoma de Madrid, En Representacion Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autonoma de Madrid","32329046"],"abstract":["INTRODUCTION: The current SARS-CoV-2 pandemic is forcing neurologists to carry out a series of adaptations in the management of multiple sclerosis. Neurologists must weigh up the need to start or continue disease-modifying treatments against the risk of infection, the risk of complications from the infection, and the risk of multiple sclerosis activity. Since this is an unprecedented situation, most decisions are being made on the basis of a theoretical approach and the criteria of each neurologist. AIMS: The aim of this study is conduct a literature search to collect available evidence on the relationship between disease-modifying therapies in multiple sclerosis and SARS-CoV-2 infection. This evidence, together with the experience of the authors in the management of patients with multiple sclerosis during the pandemic, will make it possible to offer some proposals for the treatment and follow-up of patients in this epidemiological context. DEVELOPMENT: After the literature search and our experience in the management of patients, a number of proposals for treatment are established for each drug, which must necessarily be individualised for each patient, since, in these exceptional circumstances, their peculiarities can affect the prognosis. CONCLUSIONS: The neurologist should be aware of current evidence to assess the risk-benefit of starting, maintaining and stopping disease-modifying therapies in multiple sclerosis during the pandemic."],"journal":"Rev Neurol","authors":["Costa-Frossard, L","Moreno-Torres, I","Meca-Lallana, V","Garcia-Dominguez, J M","En Representacion Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autonoma de Madrid, En Representacion Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autonoma de Madrid"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329046","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.33588/rn.7009.2020155","locations":["Madrid"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Prevention"],"weight":1,"_version_":1666138494736531456,"score":53.58144},{"pmid":32359409,"pmcid":"PMC7191287","title":"An Italian programme for COVID-19 infection in multiple sclerosis.","text":["An Italian programme for COVID-19 infection in multiple sclerosis.","Lancet Neurol","Sormani, Maria Pia","32359409"],"journal":"Lancet Neurol","authors":["Sormani, Maria Pia"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32359409","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/S1474-4422(20)30147-2","locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138495526109184,"score":50.18921},{"pmid":32463200,"title":"Treatment of multiple sclerosis under the COVID-19 pandemic.","text":["Treatment of multiple sclerosis under the COVID-19 pandemic.","Tidsskr Nor Laegeforen","Holmoy, Trygve","Torkildsen, Oivind","Bo, Lars","32463200"],"journal":"Tidsskr Nor Laegeforen","authors":["Holmoy, Trygve","Torkildsen, Oivind","Bo, Lars"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463200","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.4045/tidsskr.20.0333","weight":0,"_version_":1668079521299955712,"score":49.98456},{"pmid":32371550,"title":"COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.","text":["COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.","Neurol Neuroimmunol Neuroinflamm","Barzegar, Mahdi","Mirmosayyeb, Omid","Nehzat, Nasim","Sarrafi, Reza","Khorvash, Farzin","Maghzi, Amir-Hadi","Shaygannejad, Vahid","32371550"],"journal":"Neurol Neuroimmunol Neuroinflamm","authors":["Barzegar, Mahdi","Mirmosayyeb, Omid","Nehzat, Nasim","Sarrafi, Reza","Khorvash, Farzin","Maghzi, Amir-Hadi","Shaygannejad, Vahid"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32371550","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1212/NXI.0000000000000753","e_drugs":["Fingolimod Hydrochloride"],"topics":["Case Report"],"weight":1,"_version_":1666138496386990081,"score":47.903915}]}